Innovations in Biotechnology and Medical Sciences

CAR T-Cell Therapy for treatment of Cancer

Note4Students

From UPSC perspective, the following things are important :

Prelims level: CAR T-Cell Cancer Therapy

Mains level: Not Much

cancer

The new CAR T-Cell Immunotherapy holds promise for Ovarian Cancer patients over other forms of treatment.

What are CAR T-cells?

  • Chimeric antigen receptor (CAR) T-cell therapies represent a quantum leap in the sophistication of cancer treatment.
  • Unlike chemotherapy or immunotherapy, which require mass-produced injectable or oral medication, CAR T-cell therapies use a patient’s own cells.
  • They are modified in the laboratory to activate T-cells, a component of immune cells, to attack tumours.
  • These modified cells are then infused back into the patient’s bloodstream after conditioning them to multiply more effectively.
  • The cells are even more specific than targeted agents and directly activate the patient’s immune system against cancer, making the treatment more clinically effective.
  • This is why they’re called ‘living drugs’.

How does the therapy work?

  • In CAR T-cell therapy, the patient’s blood is drawn to harvest T-cells which are immune cells that play a major role in destroying tumour cells.
  • Researchers modify these cells in the laboratory so that they express specific proteins on their surface, known as chimeric antigen receptors (CAR).
  • They have an affinity for proteins on the surface of tumour cells.
  • This modification in the cellular structure allows CAR T-cells to effectively bind to the tumour and destroy it.
  • The final step in the tumour’s destruction involves its clearance by the patient’s immune system.

Where is it used?

  • As of today, CAR T-cell therapy has been approved for leukaemias (cancers arising from the cells that produce white blood cells) and lymphomas (arising from the lymphatic system).
  • These cancers occur through the unregulated reproduction of a single clone of cells, that is, following the cancerous transformation of a single type of cell, it produces millions of identical copies.
  • As a result, the target for CAR T-cells is consistent and reliable.
  • CAR T-cell therapy is also used among patients with cancers that have returned after an initial successful treatment or which haven’t responded to previous combinations of chemotherapy or immunotherapy.
  • Its response rate is variable. In certain kinds of leukaemias and lymphomas, the efficacy is as high as 90%, whereas in other types of cancers it is significantly lower.

How widespread is its use?

  • The complexity of preparing CAR T-cells has been a major barrier to their use.
  • The first clinical trial showing they were effective was published almost a decade ago; the first indigenously developed therapy in India was successfully performed only in 2022.
  • The technical and human resources required to administer this therapy are also considerable.
  • Treatments in the US cost more than a million dollars.
  • Trials are underway in India, with companies looking to indigenously manufacture CAR T-cells at a fraction of the cost.
  • The preliminary results have been encouraging.

What are conventional cancer therapies?

  • The three major forms of treatment for any cancer are surgery (removing the cancer), radiotherapy (delivering ionising radiation to the tumour), and systemic therapy (chemotherapy- administering medicines that act on the tumour only).
  • Surgery and radiotherapy have been refined significantly over time whereas advances in systemic therapy have been unparalleled.
  • A new development on this front, currently holding the attention of many researchers worldwide, is the CAR T-cell therapy.

Will this therapy be expensive in India as well?

  • In India, introducing any new therapy faces the twin challenges of cost and value.
  • Critics argue that developing facilities in India may be redundant and/or inappropriate as even when it becomes cheaper, CAR T-cell therapy will be unaffordable to most Indians.
  • Those who are affluent and require the therapy currently receive it abroad anyway.
  • While this is true, it may be the right answer to the wrong question.
  • Having access to a global standard of care is every patient’s right; how it can be made more affordable can be the next step.

 

Crack Prelims 2023! Talk to our Rankers

(Click) FREE 1-to-1 on-call Mentorship by IAS-IPS officers | Discuss doubts, strategy, sources, and more

Get an IAS/IPS ranker as your 1: 1 personal mentor for UPSC 2024

Attend Now

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

JOIN THE COMMUNITY

Join us across Social Media platforms.

💥Mentorship New Batch Launch
💥Mentorship New Batch Launch